Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.20.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Current Assets    
Cash and cash equivalents $ 10,085 $ 15,045
Prepaid expenses and other current assets 1,084 1,381
Total Current Assets 11,169 16,426
Property and equipment, net 309 367
Right of use asset 386 419
Deposits and other assets 23 23
Total Assets 11,887 17,235
Current Liabilities:    
Accounts payable 1,247 2,315
Accrued expenses 1,062 1,776
Accrued employee benefits 309 935
Lease liability 258 249
Total Current Liabilities 2,876 5,275
Lease liability - Long term 405 473
Total Liabilities 3,281 5,748
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding 12,606 12,544
Stockholders' Deficit:    
Common stock, $0.001 par value; 200,000,000 shares authorized, 17,741,803, issued and 17,739,475 outstanding and 16,808,758, issued and 16,806,430 outstanding 18 17
Additional paid-in capital 233,735 232,580
Accumulated deficit (238,967) (235,537)
Total Synthetic Biologics, Inc. and Subsidiaries Deficit (1,122) 1,821
Non-controlling interest (2,878) (2,878)
Total Stockholders' Deficit (4,000) (1,057)
Total Liabilities and Stockholders' Deficit 11,887 17,235
Series B Preferred Stock [Member]    
Stockholders' Deficit:    
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 6,565 issued and outstanding and 7,638 issued and outstanding 4,092 4,761
Total Stockholders' Deficit $ 4,092 $ 4,761